Enhancing cancer treatment using natural killer cells in dogs with soft tissue sarcoma
Targeting MIC to Augment Adoptive NK Therapy Using the Canine Soft Tissue Sarcoma Model
This study is looking at a new way to help treat soft tissue sarcoma in dogs by using special immune cells called natural killer cells, along with a targeted antibody, to make the treatment more effective and hopefully improve outcomes for our furry friends.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University at Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-11166856 on NIH RePORTER |
What this research studies
This research investigates how to improve cancer therapy by using natural killer (NK) cells, which are a type of immune cell, in the treatment of soft tissue sarcoma in dogs. The study focuses on a specific antibody that targets a molecule called MIC, which is found in many solid tumors. By using this antibody, the researchers aim to enhance the effectiveness of NK cells in attacking cancer cells, potentially leading to better outcomes for patients. The approach involves testing this therapy in a canine model to better understand its effects before considering human applications.
Who could benefit from this research
Good fit: Ideal candidates for this research are dogs diagnosed with soft tissue sarcoma that may benefit from enhanced immune therapies.
Not a fit: Patients who do not have soft tissue sarcoma or those with other types of cancer may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments for both dogs and potentially humans by improving the immune response against tumors.
How similar studies have performed: Previous research has shown promise in using NK cells for cancer treatment, but this specific approach targeting MIC in a canine model is relatively novel.
Where this research is happening
Chicago, United States
- Northwestern University at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Pollack, Seth M — Northwestern University at Chicago
- Study coordinator: Pollack, Seth M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.